reintroducing the IV antifungal Cancidas

Merck-Frosst is reintroducing the IV antifungal Cancidas.

Cancidas (caspofungin acetate) was originally marketed last fall...but wasn't widely promoted due to supply problems.

The shortage got so bad that by April the drug was no longer available to new patients. Now the shortage is over.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get quote